TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.

Piotr Wiland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.